Notice: amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `pre_get_posts` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the theme with slug `publisher` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /home/runcloud/webapps/techilive/wp-includes/functions.php on line 5313
Versatile coronavirus antibody may be starting point for broader-acting vaccines: A special type of antibody is produced in patients who've had COVID-19 as well as less-serious coronaviruses that cause colds - TechiLive.in

Versatile coronavirus antibody may be starting point for broader-acting vaccines: A special type of antibody is produced in patients who’ve had COVID-19 as well as less-serious coronaviruses that cause colds

0

Even before the COVID-19 pandemic, most people in the United States already had been sick with a coronavirus, albeit a far less dangerous one. That’s because at least four coronaviruses in the same general family as SARS-CoV-2 cause the benign yet annoying illness known as the common cold.

In a new study that appears in Nature Communications, scientists from Scripps Research investigated how the immune system’s previous exposure to cold-causing coronaviruses impact immune response to COVID-19. In doing so, they discovered one cross-reactive coronavirus antibody that’s triggered during a COVID-19 infection.

The findings will help in the pursuit of a vaccine or antibody treatment that works against most or all coronaviruses, says senior author Raiees Andrabi, PhD, an investigator in the Department of Immunology and Microbiology.

Loading...

“By examining blood samples collected before the pandemic and comparing those with samples from people who had been sick with COVID-19, we were able to pinpoint antibody types that cross reacted with benign coronaviruses as well as SARS-CoV-2,” says Andrabi, who works closely with the laboratory of professor Dennis Burton, PhD.

In later tests, the antibody also neutralized SARS-CoV-1, the coronavirus that causes SARS, or severe acute respiratory syndrome.

“We were able to determine that this type of cross-reactive antibody is likely produced by a memory B cell that’s initially exposed to a coronavirus that causes the common cold, and is then recalled during a COVID-19 infection,” Andrabi says.

Loading...

Memory B cells are an essential part of the immune system. They “remember” initial disease threats and can circulate in the bloodstream for decades, ready to be called back into action if the threat emerges again. These cells are responsible for producing targeted antibodies.

Loading...

The discovery may be an important step in the eventual development of a pan-coronavirus vaccine, which would be able to protect against potential coronaviruses that emerge in the future, says Burton, the James and Jessie Minor Chair in Immunology in the Department of Immunology & Microbiology at Scripps Research.

“Another deadly coronavirus will likely emerge again in the future — and when it does, we want to be better prepared,” Burton says. “Our identification of a cross-reactive antibody against SARS-CoV-2 and the more common coronaviruses is a promising development on the way to a broad-acting vaccine or therapy.”

Burton’s lab is also investigating broadly neutralizing antibodies that can be harnessed to protect against many forms of influenza, which is another virus likely to cause a pandemic in the future.

Loading...

In the new study, the team used electron microscopy to understand how the cross-reactive antibody is able to neutralize a range of coronaviruses. They saw that it mostly binds to the base of the virus’s spike protein, an area that doesn’t change much from strain to strain, says first author Ge “Sophie” Song, a graduate student in the Burton laboratory.

“The study highlights how important it is to fully understand the nature of preexisting immunity, especially in regard to coronaviruses,” Song says. “Earlier exposure to a coronavirus, even a benign virus that causes colds, impacts the nature and level of antibodies produced when more serious coronavirus threats emerge.”

The study, “Cross-reactive serum and memory B-cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection,” is authored by Ge Song, Wan-ting He, Sean Callaghan, Fabio Anzanello, Deli Huang, James Ricketts, Jonathan Torres, Nathan Beutler, Linghang Peng, Sirena Vargas, Jon Cassell, Mara Parren, Linlin Yang, Caroline Ignacio, Davey Smith, James Voss, David Nemazee, Andrew Ward, Thomas Rogers, Dennis Burton and Raiees Andrabi.

Loading...

Funding for this research was provided by NIH CHAVD and R01 awards, the IAVI Neutralizing Antibody Center, the Bill & Melinda Gates Foundation, the John and Mary Tu Foundation and the James B. Pendleton Charitable Trust.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

Loading...

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Loading...
Denial of responsibility! TechiLive.in is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – admin@techilive.in. The content will be deleted within 24 hours.

Leave a comment